期刊文献+

多发性骨髓瘤患者中POSTN和Ki67表达水平变化及与预后的相关性

Changes of POSTN and Ki67 expression levels in patients with multiple myeloma and their correlation with prognostic
原文传递
导出
摘要 目的检测骨膜蛋白(POSTN)和Ki67在多发性骨髓瘤(MM)患者血浆中的表达水平,并分析其与预后的相关性。方法选取遂宁市中心医院血液科2018年6月-2021年4月收治的88例首次诊断为MM患者作为研究对象,根据R-ISS国际预后分期将MM患者分为Ⅰ期(n=22)、Ⅱ期(n=30)、Ⅲ期(n=36);40名临床基本资料相匹配的健康志愿者作为对照组。采用RT-qPCR法分别测定外周血血浆中POSTN和Ki67表达水平,并随访评估患者预后复发情况,采用生存曲线Kaplan-Meier法和Log-rank检验分析POSTN和Ki67水平与患者预后生存状况的关系。结果与对照组比较,Ⅰ、Ⅱ、Ⅲ期MM患者血清β2微球蛋白和乳酸脱氢酶水平显著升高,白蛋白水平明显降低,差异均有统计学意义(F=244.298、283.843、881.190,P均<0.001);Ⅰ、Ⅱ、Ⅲ期MM患者血浆POSTN和Ki67mRNA水平显著高于对照组,差异均有统计学意义(F=159.068、396.522,P均<0.001)。末次随访,Ⅰ期患者总生存期和无进展生存期分别为(26.41±5.75)月和(23.75±7.25)月,Ⅱ期患者总生存期和无进展生存期分别为(24.57±8.33)月和(20.27±8.87)月,Ⅲ期患者总生存期和无进展生存期分别为(22.19±8.75)月和(17.43±8.63)月。Ⅰ期患者随访期间总生存率为68.18%(15/22),明显高于Ⅱ期63.33%(19/30)和Ⅲ期55.56%(20/36)。Pearson相关性分析显示,患者血浆中POSTN和Ki67 mRNA水平与总生存时间(r=-0.473、-0.385,P均<0.001)和无进展生存时间(r=-0.519、-0.548,P均<0.001)成负相关。结论血浆POSTN和Ki67 mRNA表达水平与MM患者生存时间成负相关,二者对MM患者疾病进展和预后评估具有重要指导意义。 Objective To explore the expression of periostin(POSTN)and Ki67 in the plasma of multiple myeloma(MM)patients and analyze their correlation with prognosis.Methods A total of 88 patients with MM admitted to Suining Central Hospital from June 2018 to April 2021 were retrospectively studied,MM patients were classified as stageⅠ(n=22),stageⅡ(n=30)and stageⅢ(n=36)according to R⁃ISS.Forty healthy volunteers mathched for basic clinical information served as the control group.The expression levels of POSTN and Ki67 in peripheral blood were determined by RT⁃qPCR,and the prognosis and recurrence of the patients were evaluated after 6 months of follow⁃up.The survival curve,Kaplan⁃Meier method and log⁃rank test were used to analyze the POSTN and Ki67 levels and the prognosis and survival status of the two groups of patients.Results The levels of serumβ2 microglobulin and lactate dehydrogenase in MM patients of stageⅠ,ⅡandⅢwere significantly higher than those in the control group,while the levels of albumin were significantly lower,the differences were statistically significant(F=244.298,283.843,881.190;all P<0.001).The levels of plasma POSTN and Ki67 mRNA were significantly higher than those in the control group,the differences were statistically significant(F=159.068,396.522;all P<0.05).At the last follow⁃up,the overall survival and progression⁃free survival in stageⅠpatients were(26.41±5.75)months and(23.75±7.25)months,respectively;those in stageⅡpatients were(24.57±8.33)months and those in stageⅢpatients were(20.27±8.87)months,and those in stageⅢpatients were(22.19±8.75)months and those in stageⅢpatients were(17.43±8.63)months.The overall survival rate of stageⅠpatients was 68.18%(15/22),which was significantly higher than that of stageⅡpatients(63.33%,19/30)and stageⅢpatients(55.56%,20/36).Pearson correlation analysis showed that plasma POSTN and Ki67 mRNA levels were significantly negatively correlated with overall survival time(r=-0.473,-0.385;all P<0.001)and progression⁃free survival time(r=-0.519,-0.548;all P<0.001).Conclusions The levels of plasma POSTN and Ki67 mRNA were significantly negatively correlated with the survival time of MM patients,which had important guiding significance for the evaluation of disease progression and prognosis of MM patients.
作者 梁艳丽 魏容 冯麓洁 王欣 LIANG Yanli;WEI Rong;FENG Lujie;WANG Xin(Department of Clinical Laboratory,Suining Central Hospital,Suining,Sichuan 629000,China;Department of Haematology,Suining Central Hospital,Suining,Sichuan 629000,China)
出处 《热带医学杂志》 CAS 2024年第4期518-521,526,共5页 Journal of Tropical Medicine
关键词 骨膜蛋白 KI67 多发性骨髓瘤 Periosteum protein Ki67 Multiple myeloma
  • 相关文献

参考文献13

二级参考文献56

  • 1何小庆,韩锐.HL-60细胞属AML-M_2型,NB4细胞为真正的AML-M_3型[J].中华血液学杂志,1996,17(5):277-278. 被引量:7
  • 2Jun-Sheng Li,Guang-Wen Sun,Xiao-Ying Wei,Wen-Hao Tang.Expression of periostin and its clinicopathological relevance in gastric cancer[J].World Journal of Gastroenterology,2007,13(39):5261-5266. 被引量:19
  • 3Kanavaros P,Stefanaki K,Vlachonikolis J,et al.Immunohistochemical expression of the p53, p21/waf-1, RL and Ki67 proteins in multiple myeloma[].Anticancer Research.2000
  • 4Durie BGM,Salmon SE.A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival[].Cancer.1975
  • 5Dalton WS,Jove R.Drug resistance in multiple myeloma:approaches to circumvention[].Seminars in Oncology.1999
  • 6Barille S,Bataille R,Amiot M.The role of interleukin-6 and interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma[].European Cytokine Network.2000
  • 7Goodson WH,Moore DH,Ljung BM,et al.The prognostic value of proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67[].Breast Cancer Research.2000
  • 8Klein B,Zhao-Yang L,Zong Jlang G,et al.Interleukin10 and Gp130 cytokines in human multiple myeloma[].Leukemia and Lymphoma.1999
  • 9Thaler J,Fechner F,Herold M.Interleukin-6 in multiple myeloma: correlation with disease activity and Ki67 proliferation index[].Leukemia and Lymphoma.1994
  • 10Habashy HO,Powe DG,Staka CM,et al.Transferrin receptor(CD71)is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.Breast Cancer Res Treat,2010;119(2):283-293.

共引文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部